Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults
Vitamin D Metabolism Inflammation, and Cardiovascular Risk in HIV-infected Children and Young Adults
1 other identifier
observational
290
1 country
2
Brief Summary
The relationship of Vitamin D levels in children and young adults to atherosclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2011
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 4, 2011
CompletedFirst Posted
Study publicly available on registry
August 5, 2011
CompletedStudy Start
First participant enrolled
September 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedJune 28, 2016
June 1, 2016
3.3 years
August 4, 2011
June 24, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Vitamin D levels
To perform a cross-sectional analysis of blood vitamin D status among the HIV-infected children and young adults to evaluated the point prevalence fo plasma 25(OH)D levels indicating vitamin D insufficiency, deficiency and severe deficiency, and to compare the prevalence to a matched uninfected healthy control group.
One time point at entry
Study Arms (2)
HIV+
HIV Positive children or young people between the ages of 8 and 25
HIV Negative
HIV Negative matched controls by age and race
Eligibility Criteria
Any HIV+ patient between the ages of 8 and 25 and matched HIV- controls matched by age and race.
You may qualify if:
- On stable ART for at least 12 weeks for the HIV+ patients
- Cumulative duration of ART for at least 48 weeks for HIV + patients
- Healthy child/young adult with age and race matched to HIV+ patient for the HIV- controls
- Absence of HIV based on medical and medication history
You may not qualify if:
- Taking \> 800 IU of Vitamin D per day
- Parathyroid or Calcium disorders
- Acute illness and active inflammatory condition
- Chronic illnesses that include malignancy, diabetes, CAD
- Pregnancy and lactation
- Creatinine Clearance \<50 ml/min
- Hgb \< 9.0 g/dL
- AST and ALT \> 2.5 upper limits of normal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Emory Chldren's Center
Atlanta, Georgia, 30308, United States
University Hospitals Case Medical Center, Case Western Reserve University
Cleveland, Ohio, 44106, United States
Biospecimen
plasma, serum, PBMCs, urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Grace McComsey, MD
University Hospitals Cleveland Medical Center
- PRINCIPAL INVESTIGATOR
Allison Ross Eckard, MD
Emory-Children's Center
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Pediatrics and Medicine
Study Record Dates
First Submitted
August 4, 2011
First Posted
August 5, 2011
Study Start
September 1, 2011
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
June 28, 2016
Record last verified: 2016-06